Literature DB >> 28865325

Impact of cystatin C and microalbuminuria on cognitive impairment in the population of community-dwelling Japanese.

Shoko Kono1, Hisashi Adachi2, Mika Enomoto1, Ako Fukami1, Eita Kumagai1, Sachiko Nakamura1, Yume Nohara1, Nagisa Morikawa1, Erika Nakao1, Akiko Sakaue1, Tomoko Tsuru1, Yoshihiro Fukumoto1.   

Abstract

BACKGROUND AND AIMS: Cognitive impairment is an important element affecting our well-being, and as such, early diagnosis is critical today. We investigated whether serum cystatin C and microalbuminuria are associated with cognitive impairment.
METHODS: A total of 1943 subjects (774 males, 1169 females, mean age 65.8 years) took part in the investigation, and underwent a health examination in Tanushimaru, Japan, in 2009. The participants' cognitive function was evaluated using of mini-mental state examination (MMSE). We measured the levels of serum cystatin C using latex nephelometric immunoassay. Spot urine samples were used to measure microalbuminuria levels. Multivariate linear regression analyses were used to assess the relationship between MMSE scores and the level of cystatin C or microalbuminuria. All statistical analyses were performed using the SAS system.
RESULTS: The mean values of log-transformed serum cystatin C levels and log-transformed microalbuminuria were 0.95 (range 0.41-7.11) mg/L and 10.7 (range 1.1-2600) mg/g·Cr, respectively. The means of MMSE score were 27.7 ± 2.5. In the multivariate linear regression analyses adjusted for age and sex, MMSE was significantly associated with systolic blood pressure (p = 0.024, inversely), cystatin C (p = 0.046, inversely) and microalbuminuria (p = 0.019, inversely), whereas estimated glomerular filtration rate (eGFR) had an insignificant association (p = 0.197). In the multiple stepwise linear regression analysis, age, history of stroke, systolic blood pressure, serum cystatin C were independently associated with MMSE levels.
CONCLUSIONS: We demonstrated for the first time that cognitive function was significantly and inversely associated with cystatin C and microalbuminuria, in the relatively younger general population.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cognitive impairment; Cystatin C; Epidemiology; Microalbuminuria

Mesh:

Substances:

Year:  2017        PMID: 28865325     DOI: 10.1016/j.atherosclerosis.2017.08.022

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  5 in total

1.  Cystatin C promotes cognitive dysfunction in rats with cerebral microbleeds by inhibiting the ERK/synapsin Ia/Ib pathway.

Authors:  Guangna Yu; Xingyuan Sun; Li Li; Lijuan Huang; Hongbin Liu; Shuying Wang; Zhanjun Ren; Yanjiao Zhang
Journal:  Exp Ther Med       Date:  2019-12-31       Impact factor: 2.447

Review 2.  Albuminuria as a risk factor for mild cognitive impairment and dementia-what is the evidence?

Authors:  Boris Bikbov; Maria José Soler; Vesna Pešić; Giovambattista Capasso; Robert Unwin; Matthias Endres; Giuseppe Remuzzi; Norberto Perico; Ron Gansevoort; Francesco Mattace-Raso; Annette Bruchfeld; Andreja Figurek; Gaye Hafez
Journal:  Nephrol Dial Transplant       Date:  2021-12-28       Impact factor: 5.992

3.  Association between serum cystatin C level and post-stroke cognitive impairment in patients with acute mild ischemic stroke.

Authors:  Xu Yan; Huan Chen; Xiu-Li Shang
Journal:  Brain Behav       Date:  2022-02-11       Impact factor: 3.405

4.  Urinary albumin creatinine ratio associated with postoperative delirium in elderly patients undergoing elective non-cardiac surgery: A prospective observational study.

Authors:  Hui-Lian Guan; He Liu; Xiao-Yi Hu; Mannan Abdul; Ming-Sheng Dai; Xing Gao; Xue-Fen Chen; Yang Zhou; Xun Sun; Jian Zhou; Xiang Li; Qiu Zhao; Qian-Qian Zhang; Jun Wang; Yuan Han; Jun-Li Cao
Journal:  CNS Neurosci Ther       Date:  2021-08-20       Impact factor: 5.243

Review 5.  Diabetes, Albuminuria and the Kidney-Brain Axis.

Authors:  Diana Maria Ariton; Joan Jiménez-Balado; Olga Maisterra; Francesc Pujadas; María José Soler; Pilar Delgado
Journal:  J Clin Med       Date:  2021-05-27       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.